您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8473 处方药 8099 非处方药 268 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 抗癌药物->治疗淋巴瘤药物
处方药:处方药
包装规格: 500毫克/瓶
计价单位:
   
生产厂家英文名:
SPECTRUM PHARMS
该药品相关信息网址1:
http://www.sppirx.com/322-spectrum-products-late-stage-beleodaq.html
原产地英文商品名:
BELEODAQ 500mg Vial
原产地英文药品名:
BELINOSTAT
中文参考商品译名:
BELEODAQ 500毫克/瓶
中文参考药品译名:
注射用贝利司他
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Peripheral T-cell lymphoma (PTCL)
临床试验期:
完成
中文适应病症参考翻译1:
周边T细胞淋巴瘤(PTCL)
药品信息:
英文药名:Beleodaq(belinostat injection) 中文药名:注射用贝利司他 生产厂家:Spectrum药业 药品介绍 近日,美国FDA通过加速批准通道批准了Spectrum的HDAC抑制剂belinostat(商品名:Beleodaq)上市,治疗一种复发或难治性的罕见淋巴瘤—外周T细胞淋巴瘤(PTCL)。根据一项有120名复发或难治性PTCL患者参与的多中心,单臂的三期临床研究(BELIEF实验),每天静脉注射一次Beleodaq(1000毫克/平米)连续5天,有25.8%的患者表现应答,其中有10.8%的完全应答和15%的部分应答,达到一级临床终点。患者的平均应答时间为8.4个月。患者常见的副作用包括发热、贫血、恶心、呕吐和疲劳等。 批准日期:2014年7月3日;公司: Spectrum药业公司 BELEODAQ®(belinostat)注射用,为静脉给药 美国初始批准:2014 适应证和用途 Beleodaq是一种组蛋白去乙酰化酶抑制剂[histone deacetylase inhibitor]适用为有复发或难治周边T细胞淋巴瘤(PTCL)患者的治疗,这个适应证是在根据肿瘤反应率和反应时间在加速批准下批准的。尚未确定改善生存或疾病相关症状。继续批准这个适应证可能取决于在验证性试验中核实和描述临床获益。 剂量和给药方法 ⑴Beleodaq的推荐剂量是在21天疗程的第1-5天每天1次1,000mg/m2通过静脉历时30分钟输注给药。疗程可重复直至疾病进展或不可接受的毒性。 ⑵为处理不良反应可能需要终止治疗或中断有或无剂量减少25%。 剂型和规格 为注射:500mg ,冻干粉在为重建的一次性使用小瓶。 禁忌证 无 警告和注意事项 ⑴血小板减少,白细胞减少(中性粒细胞减少和淋巴细胞减少),和贫血:监视血细胞计数和对血液学毒性调整剂量。 ⑵感染:严重和致命性感染(如,肺炎和败血症)。 ⑶肝毒性:Beleodaq可能致肝毒性和肝功能测试异常。监视肝功能测试和omit或调整剂量 for 肝毒性. ⑷肿瘤溶解综合证:监视有晚期疾病和/或高肿瘤负荷患者和采取适当措施。 ⑸胚胎-胎儿毒性:当给予一位妊娠妇女Beleodaq可能致胎儿危害。忠告妇女对胎儿潜在危害和当接受Beleodaq时避免妊娠。 不良反应 最常见不良反应(>25%)是恶心,疲劳,发热,贫血,和呕吐。 特殊人群中使用 哺乳母亲:当正在用治疗时Beleodaq应忠告妇女不要哺乳。 BELEODAQ™ (belinostat) for injection a pan HDAC inhibitor BELEODAQ (belinostat) injection, powder, lyophilized, for solution [Spectrum Pharmaceuticals, Inc.] Target Indications Peripheral T-Cell Lymphoma (PTCL) Carcinoma of Unknown Primary (CUP) Non-Small Cell Lung Cancer (NSCLC) Other solid tumors and hematological malignancies Route of Administration IV Mode of Action BELEODAQ (PXD 101) is a pan HDAC inhibitor in late stage clinical development with more than 1,000+ patients treated to date. BELEODAQ is believed to inhibit enzymatic activity of class 1 and class 2 HDACs. BELEODAQ is also believed to increase in acetylation of both histone and histone proteins, resulting in cell cycle arrest, apoptosis and a decrease in cell proliferation. Status Currently in a Pivotal study in PTCL In clinical trials, BELEODAQ has shown that it may be well-tolerated, which allows for combination with traditional chemotherapy without causing excessive bone marrow toxicity. In pre-clinical studies BELEODAQ has shown to be active against multiple cancers by inhibiting cell proliferation (inhibiting cancer growth) and inducing programed cell death ("apoptosis") in tumor cells (the tumor cells are forced to self-destruct). BELEODAQ has been eva luated in a number of Phase 1 and 2 clinical trials in hematological cancers and solid tumors. Data from these trials have provided for the anti-tumor effect of BELEODAQ as monotherapy in peripheral T-cell lymphomas (PTCL) and in combination with other anti-cancer drugs for the treatment of multiple types of cancer including CUP and non-small cell lung cancer (NSCLC). To date clincal trials suggest BELEODAQ is well tolerated at full dose. The most frequent adverse events of any grade and irrespective of study design have been nausea, fatigue and vomiting. As such, it is being investigated in high doses not only alone, but also in drug combinations. In preclinical tumor models, BELEODAQ is active in cancer cells that have become resistant to existing chemotherapies. BELEODAQ could add substantial treatment value to several important drug combinations. The FDA granted approval of BELEODAQ for relapsed or refractory PTCL on July 3, 2014. Continued support from the National Cancer Institute (NCI) has helped build a comprehensive program which has identified the optimal development route for BELEODAQ. The development of BELEODAQ is planned in collaboration with the NCI, and all trials are born from laboratory data showing the most favorable methods of use and combinations. Based on available data so far, Spectrum believes that BELEODAQ has the potential to become the "best in class" pan HDAC inhibitor. The efficacy of BELEODAQ noted in ongoing clinical trials is likely to be linked to the high blood concentrations of drug achieved using intravenous ("IV") dosing. This high blood concentration may not be attainable for other pan HDAC inhibitors. BELEODAQ has also exhibited a favourable safety profile.
更新日期: 2015-03-01
附件:
201482822330235.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com